论文部分内容阅读
目的观察罗格列酮治疗对伴早期肾病的2型糖尿病患者血转化生长因子β1(TGF-β1)的影响。方法 52例早期糖尿病肾病(DN)患者随机分为罗格列酮治疗组及对照组。比较两组治疗前后TGF-β1、尿白蛋白排泄率(UAER)、糖脂代谢、肾功能指标的变化。结果两组治疗后TGF-β1、UAER较治疗前比较均下降,但治疗组更明显(P<0.01),两组治疗后效果比较差异有统计学意义(P<0.01)。治疗组治疗后TG下降(P<0.01)。两组FPG、2hPG、HbA_1c、TC、BUN、Cr治疗前后比较,差异无统计学意义(P>0.05)。结论加用罗格列酮则能减轻肾损害。
Objective To observe the effect of rosiglitazone on blood transforming growth factor-β1 (TGF-β1) in type 2 diabetic patients with early nephropathy. Methods 52 cases of early diabetic nephropathy (DN) were randomly divided into rosiglitazone treatment group and control group. The changes of TGF-β1, urinary albumin excretion rate (UAER), glucose and lipid metabolism, renal function indexes before and after treatment were compared between the two groups. Results After treatment, the levels of TGF-β1 and UAER in both groups decreased compared with those before treatment, but the treatment group was more obvious (P <0.01). The difference between the two groups after treatment was statistically significant (P <0.01). The treatment group TG decreased (P <0.01). There were no significant differences in the levels of FPG, 2hPG, HbA_1c, TC, BUN and Cr between the two groups before and after treatment (P> 0.05). Conclusions Adding rosiglitazone can reduce renal damage.